Ofra Novoplansky

441 total citations
12 papers, 217 citations indexed

About

Ofra Novoplansky is a scholar working on Oncology, Molecular Biology and Otorhinolaryngology. According to data from OpenAlex, Ofra Novoplansky has authored 12 papers receiving a total of 217 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 6 papers in Molecular Biology and 3 papers in Otorhinolaryngology. Recurrent topics in Ofra Novoplansky's work include Peptidase Inhibition and Analysis (4 papers), Head and Neck Cancer Studies (3 papers) and Lung Cancer Treatments and Mutations (3 papers). Ofra Novoplansky is often cited by papers focused on Peptidase Inhibition and Analysis (4 papers), Head and Neck Cancer Studies (3 papers) and Lung Cancer Treatments and Mutations (3 papers). Ofra Novoplansky collaborates with scholars based in Israel, United States and Germany. Ofra Novoplansky's co-authors include Moshe Elkabets, Sankar Jagadeeshan, Ksenia M. Yegodayev, Manu Prasad, Jonathan Zorea, Limor Cohen, Ben‐Zion Joshua, Michael Brandeis, Ron R. Kopito and Elham Alsahafi and has published in prestigious journals such as Proceedings of the National Academy of Sciences, PLoS ONE and Scientific Reports.

In The Last Decade

Ofra Novoplansky

12 papers receiving 214 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ofra Novoplansky Israel 8 132 93 31 31 27 12 217
Irati Garmendia Spain 8 112 0.8× 98 1.1× 44 1.4× 54 1.7× 42 1.6× 12 219
Xian-Zi Yang China 8 225 1.7× 95 1.0× 23 0.7× 95 3.1× 28 1.0× 8 320
Francesc Muyas United Kingdom 8 115 0.9× 40 0.4× 29 0.9× 97 3.1× 18 0.7× 16 204
Carolina Carneiro Soares Macedo Brazil 9 163 1.2× 78 0.8× 13 0.4× 95 3.1× 24 0.9× 13 266
Karina E. Gomez United States 7 156 1.2× 120 1.3× 27 0.9× 79 2.5× 66 2.4× 9 268
Christina Möller‐Koop Germany 9 111 0.8× 49 0.5× 72 2.3× 64 2.1× 23 0.9× 18 192
Guo-Rung You Taiwan 9 199 1.5× 40 0.4× 26 0.8× 160 5.2× 30 1.1× 13 301
Dale W. Lewis United States 7 227 1.7× 180 1.9× 12 0.4× 106 3.4× 15 0.6× 8 318
Tugs‐Saikhan Chimed United States 8 184 1.4× 143 1.5× 32 1.0× 85 2.7× 79 2.9× 9 304
Valentina Salvati Italy 7 165 1.3× 101 1.1× 78 2.5× 46 1.5× 18 0.7× 7 279

Countries citing papers authored by Ofra Novoplansky

Since Specialization
Citations

This map shows the geographic impact of Ofra Novoplansky's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ofra Novoplansky with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ofra Novoplansky more than expected).

Fields of papers citing papers by Ofra Novoplansky

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ofra Novoplansky. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ofra Novoplansky. The network helps show where Ofra Novoplansky may publish in the future.

Co-authorship network of co-authors of Ofra Novoplansky

This figure shows the co-authorship network connecting the top 25 collaborators of Ofra Novoplansky. A scholar is included among the top collaborators of Ofra Novoplansky based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ofra Novoplansky. Ofra Novoplansky is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

12 of 12 papers shown
1.
Novoplansky, Ofra, Sankar Jagadeeshan, Manu Prasad, et al.. (2024). Dual inhibition of HERs and PD-1 counteract resistance in KRASG12C-mutant head and neck cancer. Journal of Experimental & Clinical Cancer Research. 43(1). 308–308. 1 indexed citations
2.
Novoplansky, Ofra, Sankar Jagadeeshan, Jonathan Zorea, et al.. (2023). Activation of the EGFR / PI3K / AKT pathway limits the efficacy of trametinib treatment in head and neck cancer. Molecular Oncology. 17(12). 2618–2636. 19 indexed citations
3.
Yegodayev, Ksenia M., et al.. (2023). Developing a dual VEGF/PDL1 inhibitor based on high-affinity scFv heterodimers as an anti-cancer therapeutic strategy. Scientific Reports. 13(1). 11923–11923. 9 indexed citations
4.
Jagadeeshan, Sankar, Ofra Novoplansky, Oded Cohen, et al.. (2023). New insights into RAS in head and neck cancer. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 1878(6). 188963–188963. 5 indexed citations
5.
Novoplansky, Ofra, et al.. (2022). Worldwide Prevalence and Clinical Characteristics of RAS Mutations in Head and Neck Cancer: A Systematic Review and Meta-Analysis. Frontiers in Oncology. 12. 838911–838911. 15 indexed citations
6.
Greenshpan, Yariv, Ksenia M. Yegodayev, Ofra Novoplansky, et al.. (2022). The Contribution of the Minimal Promoter Element to the Activity of Synthetic Promoters Mediating CAR Expression in the Tumor Microenvironment. International Journal of Molecular Sciences. 23(13). 7431–7431. 5 indexed citations
7.
Liju, Vijayasteltar Belsamma, Nikhil Ponnoor Anto, Ilan Smoly, et al.. (2021). Unraveling the hidden role of a uORF-encoded peptide as a kinase inhibitor of PKCs. Proceedings of the National Academy of Sciences. 118(40). 30 indexed citations
8.
9.
10.
Yegodayev, Ksenia M., Ofra Novoplansky, Manu Prasad, et al.. (2020). TGF-Beta-Activated Cancer-Associated Fibroblasts Limit Cetuximab Efficacy in Preclinical Models of Head and Neck Cancer. Cancers. 12(2). 339–339. 47 indexed citations
11.
Novoplansky, Ofra, Matthew G. Fury, Manu Prasad, et al.. (2019). MET activation confers resistance to cetuximab, and prevents HER2 and HER3 upregulation in head and neck cancer. International Journal of Cancer. 145(3). 748–762. 24 indexed citations
12.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Irati Garmendia Breakdown of academic impact, for papers by Xian-Zi Yang Breakdown of academic impact, for papers by Francesc Muyas Breakdown of academic impact, for papers by Carolina Carneiro Soares Macedo Breakdown of academic impact, for papers by Karina E. Gomez Breakdown of academic impact, for papers by Christina Möller‐Koop Breakdown of academic impact, for papers by Guo-Rung You Breakdown of academic impact, for papers by Dale W. Lewis Breakdown of academic impact, for papers by Tugs‐Saikhan Chimed Breakdown of academic impact, for papers by Valentina Salvati
Rankless by CCL
2026